ர் ப்ரெஸ்டந் கொத்தனார் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ர் ப்ரெஸ்டந் கொத்தனார். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ர் ப்ரெஸ்டந் கொத்தனார் Today - Breaking & Trending Today

Amarin Corp. (AMRN) Highlights Multiple Scientific Findings for VASCEPA and Its Unique Active Ingredient at ACC

Amarin Corp. (AMRN) Highlights Multiple Scientific Findings for VASCEPA and Its Unique Active Ingredient at ACC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , San Francisco , R Preston Mason , Suvasini Lakshmanan , Craig Granowitz , Steven Ketchum , Xiaowen Wang , Andrewp Ambrosy , Kaiser Permanente , American College Of Cardiology , Vascular Center , Harvard Medical School , Lundquist Institute At , Kaiser Permanente San Francisco Medical Center , Amarin Corporation , American College , Annual Scientific Session , Clinical Data , Hospital Heart , Lundquist Institute , Coronary Computed Tomography Angiography , Fractional Flow Reserve Computed Tomography , Action Insights , Kaiser Permanente Northern California , Audio Webcast Informationamarin , While Amarin ,

Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results

Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results
December 14, 2020 05:00 ET
| Source:
Amarin Corporation plc
Amarin Corporation plc
Bedminster, New Jersey, UNITED STATES
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in outpatient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose
Amarin to Webcast Discussion of Presented Data Today, Monday, December 14, 2020 at 8:00 a.m., ....

New York , United States , United Arab Emirates , Craig Granowitz , Steven Ketchum , Michael Miller , Coll Cardiol , Clin Cardiol , K Kim Ed , Alina Kolomeyer , R Preston Mason , Richard Dunbar , El Kebir , Deepakl Bhatt , Kaiser Permanente , American Heart Association , Elucida Research , Perelman School Of Medicine , Therapeutics Inc , Journal Of The American College Cardiology , Fish Oil Dietary , A Report From The American Heart Association , Antimicrobial Properties Of Eicosapentaenoic Acid , National Lipid Association , Harvard Medical School , Professor Of Medicine At Harvard Medical School ,